Compare CVS Health Corp (CVS) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Toyota Motor Corp — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while Toyota Motor Corp trades at $184.37 (market cap $216.99B). The key difference: Toyota Motor Corp is the larger of the two by market cap, and Toyota Motor Corp pays the higher dividend (3.43%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Toyota Motor Corp for 116 Days on average.
| CVS | TM | |
|---|---|---|
Market Cap | $112.49B | $216.99B |
Volume | 8,467,392 | 314,929 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $248.29 |
52-Week Low | $70.08 | $166.50 |
Typical Hold Time | 83 Days | 116 Days |
Enterprise Value | $174.83B | $410.32B |
Dividend Yield | 3.02% | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Toyota Motor trades at $182.91, down 1.43% with bearish technical signals but attractive valuation metrics including P/E of 8.22 and P/B of 0.92. The company reported strong Q2 2026 earnings beat with EPS of $7.57 versus $4.68 expected, though revenue growth has moderated to 6.5% year-over-year. Recent news highlights Toyota's expanding electrified vehicle lineup and U.S. market share gains, while facing production challenges from Thailand floods and China sales weakness.
Toyota presents a value opportunity with solid profitability (8.63% net margin) and consistent earnings beats, but faces near-term headwinds from production disruptions and competitive pressures. Analyst consensus leans cautious with 62.5% hold ratings, suggesting the stock may consolidate near current levels despite attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
